Do you want to read an article? Please log in or register.
Better 10-Year Cerebrovascular Outcome After Transplant Than on Standard-Care in Sickle Cell Anemia: DREPAGREFFE Trial
Non-Malignant Blood Disorders
Related content
Head and Neck Cancer
Randomized Controlled Trials Comparing the Standard of Care to Alternative Treatments in Patients with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma: A Systematic Literature Review
Adv Ther
Mojebi A, Tang Y, Keeping S, Merchant S, Bidadi B, Zheng D
doi: 10.1007/s12325-026-03604-5
Non-Malignant Blood Disorders
RBC Alloimmunization Impacts Pediatric Sickle Cell Disease Transplant Outcomes and Transfusion Burden: A STAR Registry Report
Am J Hematol
Inam Z, Stenger E, John TD, Liu K, Gillespie S, Shah R, Chellapandian D, Bhatia M, Chaudhury S, Eckrich MJ, Guilcher GMT, Hendrickson JE, Hulbert ML, Jaroscak JJ, Kasow KA, Camacho-Bydume C, Ngwube A, Olson TS, Rangarajan HG, Horan JT, Krishnamurti L, Shenoy S, Abraham A, Nickel RS
doi: 10.1002/ajh.70200
Genitourinary Cancer
Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial
Lancet Oncol
Nilsson P, Gunnlaugsson A, Beckman L, Widmark A, Fransson P, Hoyer M, Lagerlund M, Kindblom J, Johansson B, Björnlinger K, Ginman C, Olsson M, Agrup M, Kjellén E, Zackrisson B, Tavelin B, Franzén L, Anderson H, Thellenberg Karlsson C
doi: 10.1016/S1470-2045(25)00656-4
Leukemia
Impact of minimal residual disease on the outcome of hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia within the FORUM Trial
Haematologica
Balduzzi A, Glogova E, Peters C, Sedlacek P, Dalle JH, Locatelli F, Meisel R, Burkhardt B, Buechner J, Wachowiak J, Bierings M, Staciuk R, Graphakos S, Güngör T, Yesilipek A, Svec P, Palma J, Krivan G, Diaz-de-Heredia C, Limido F, Ansari M, Kalwak K, Bader P, Ifversen M
doi: 10.3324/haematol.2025.287456
Lymphoma
Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study
J Clin Oncol
Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Chow VA, Montheard S, Santamaria J, Colicino S, Ogasawara K, Stepan L, Liu FF, Abramson JS
doi: 10.1200/JCO-25-00399
Gynecologic Cancer
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial
★ 3
Recommended and commented by
Dr Andreas Müller, Faculty Member
★ 1
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
Lancet Oncol
Post CCB, de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Leary A, Ottevanger PB, McCormack M, Khaw P, D'Amico R, Fyles A, Chargari C, Kitchener HC, Do V, Lissoni A, Provencher D, Genestie C, Nijman HW, Whitmarsh K, Jürgenliemk-Schulz IM, Feeney A, Lutgens LCHW, Bouma J, Leon-Castillo A, Nout RA, Putter H, Bosse T, Creutzberg CL
doi: 10.1016/S1470-2045(25)00379-1
Lung, Respiratory and Thoracic Cancer
Real-life management and outcomes of octogenarians with non-small-cell lung cancer: A 10-year evolution
Eur J Cancer
Corre R, Monnet I, Moreau L, Pinsolle J, Hominal S, Campana M, Chikouche R, Slaouti P, Tavernier JY, Clarot C, Kuntz P, Fouet K, Rabut H, Dehette S, Thirard L, Paysse M, Nunes D, Letierce A, Morel H, Debieuvre D, Study Group KBP-2020-CPHG
doi: 10.1016/j.ejca.2026.116845
Genitourinary Cancer
Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: 10-Year Outcomes of the FLAME Trial
J Clin Oncol
Menne Guricová K, Draulans C, Pos FJ, Kerkmeijer LGW, Monninkhof EM, Smeenk RJ, Kunze-Busch M, de Boer HCJ, van der Voort van der Zyp JRN, Haustermans K, van der Heide UA
doi: 10.1200/JCO-25-00274
RECOMMENDED
Breast Cancer
Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial
★ 1
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
Lancet Oncol
Yuan J, Bi XW, Hua X, Huang H, Cai L, Zhao L, Chen QJ, Chen XX, Wang XL, Lin Y, Zhang AQ, Zhong YY, Xu F, Huang JJ, An X, Shi YX, Wang X, Wang SS, Xue C, Yuan ZY
doi: 10.1016/S1470-2045(25)00545-5